Stockscreener 앱 받기
5.73
2.55%
-0.15
시간 외 거래:
5.70
-0.03
-0.52%
전일 마감가:
$5.88
열려 있는:
$5.88
하루 거래량:
944.49K
Relative Volume:
0.73
시가총액:
$344.58M
수익:
$217.78M
순이익/손실:
$-239.55M
주가수익비율:
-1.4151
EPS:
-4.0492
순현금흐름:
$-127.30M
1주 성능:
-6.37%
1개월 성능:
-8.76%
6개월 성능:
-13.83%
1년 성능:
+25.11%
1일 변동 폭
$5.61
$5.93
1주일 범위
$5.61
$6.28
52주 변동 폭
$4.14
$9.94
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
명칭
Vanda Pharmaceuticals Inc
전화
202-734-3400
주소
2200 PENNSYLVANIA AVE NW, WASHINGTON
Compare VNDA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VNDA
Vanda Pharmaceuticals Inc
|
5.73 | 353.60M | 217.78M | -239.55M | -127.30M | -4.0492 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-05 | 개시 | Truist | Buy |
| 2025-11-05 | 개시 | B. Riley Securities | Buy |
| 2024-10-31 | 개시 | H.C. Wainwright | Buy |
| 2024-07-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-02-25 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-05-12 | 개시 | BofA Securities | Buy |
| 2021-01-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-10-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-06-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-03-16 | 다운그레이드 | Oppenheimer | Perform → Underperform |
| 2020-03-12 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-11-07 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2019-08-01 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-07-25 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-12-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2018-12-04 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2018-12-04 | 재확인 | Jefferies | Buy |
| 2018-11-08 | 재개 | Jefferies | Buy |
| 2018-09-21 | 재개 | Oppenheimer | Outperform |
| 2018-05-23 | 개시 | Citigroup | Buy |
| 2018-01-19 | 개시 | Seaport Global Securities | Buy |
| 2017-09-14 | 재확인 | Piper Jaffray | Overweight |
| 2017-06-27 | 재개 | Piper Jaffray | Overweight |
| 2017-05-26 | 개시 | H.C. Wainwright | Buy |
| 2017-04-12 | 개시 | Oppenheimer | Outperform |
| 2016-11-09 | 개시 | Aegis Capital | Buy |
| 2016-10-06 | 재개 | Jefferies | Buy |
모두보기
Vanda Pharmaceuticals Inc 주식(VNDA)의 최신 뉴스
Watch VANDA Pharmaceuticals Berlin Tennis Open / Court 1 | Disney+ - Disney Plus
Why Did Vanda Pharmaceuticals Stock Slide 7% Pre-Market Today? - Stocktwits
Watch VANDA Pharmaceuticals Berlin Tennis Open / Steffi Graf Stadion | Disney+ - Disney Plus
VNDA Stock Soars 40% Overnight After Bysanti Approval: What’s The Next Catalyst And How Much Upside Remains? - Stocktwits
Vanda Stock Draws Heavy Buzz Ahead Of FDA Verdict On Bysanti For Bipolar, Schizophrenia - Stocktwits
Vanda Pharmaceuticals Stock Price Forecast. Should You Buy VNDA? - StockInvest.us
VNDA Stock Rises After Hours On Commercial Launch Of Motion Sickness Drug - Stocktwits
VNDA Stock Rallies After-Hours As FDA Approves Schizophrenia, Bipolar Disorder Drug - Stocktwits
80,000-share RSU grant to Vanda (VNDA) SVP and General Counsel - Stock Titan
Vanda Pharmaceuticals (VNDA) director granted 41,600 RSU shares vesting in 2027 - Stock Titan
Vanda (NASDAQ: VNDA) director awarded 41,600 RSU-based shares - Stock Titan
Vanda Pharmaceuticals (VNDA) director receives 41,600-share RSU award - Stock Titan
Vanda Pharmaceuticals (VNDA) director receives 41,600-share RSU grant - Stock Titan
Vanda Pharmaceuticals (VNDA) grants director 41,600 RSUs vesting in 2027 - Stock Titan
Vanda Pharmaceuticals (VNDA) SVP McGuire reports RSU awards vesting through 2029 - Stock Titan
Vanda Pharma Stock Rises Pre-Market After FDA Accepts Imsidolimab Filing For Rare Skin Disorder - Stocktwits
Vanda Pharmaceuticals 2026 Annual Meeting Results: Director Elections, Auditor Ratification, and Plan Amendment Approved - minichart.com.sg
Vanda (NASDAQ: VNDA) investors approve directors, auditor and equity plan shares - Stock Titan
Earnings call transcript: Vanda Pharmaceuticals misses Q1 2026 forecasts, stock rises - Investing.com
Analysts Offer Insights on Healthcare Companies: Vanda (VNDA), ArriVent BioPharma, Inc. (AVBP) and Medtronic (MDT) - The Globe and Mail
Gastroparesis Market Shows Strong Future Potential with Increasing Industry Investments by 2036 – DelveInsight | Vanda Pharma, Dr. Falk Pharma GmbH, Alfasigma S.p.A., PTC Therapeutics, CinDome Pharma - Barchart.com
Gastroparesis Market Shows Strong Future Potential with - openPR.com
Vanda Pharmaceuticals stock rating reiterated at Buy by H.C. Wainwright - Investing.com
Why did Vanda Pharmaceuticals stock slide 7% pre-market today? - MSN
Earnings call transcript: Vanda Pharmaceuticals Q1 2026 misses EPS forecast, stock drops - Investing.com Nigeria
Vanda Pharmaceuticals (VNDA) Shares Rise 3.75% as Stock Tests Key ResistanceWMA Signal - The Legal Advocate
H.C. Wainwright Maintains Vanda Pharmaceuticals(VNDA.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan - GuruFocus
Vanda gets orphan drug status in Japan for imsidolimab By Investing.com - Investing.com Australia
Vanda Pharmaceuticals (VNDA) Secures Orphan Drug Status in Japan - GuruFocus
Vanda gets orphan drug status in Japan for imsidolimab - Investing.com
Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis - Barchart
Vanda a new buy at B. Riley on 'historic discount' - MSN
Vanda Pharmaceuticals Inc (VNDA) Stock Price, Quote, News & History - Benzinga
Vanda Pharmaceuticals Q3 Earnings Preview - MSN
Vanda (VNDA) director donates 25,836 shares of common stock - Stock Titan
VNDA: 2026 revenue guidance raised on new launches, with BYSANTI and NEREUS set to drive future growth - TradingView
How The Vanda Pharmaceuticals (VNDA) Investment Story Is Shifting With BYSANTI And Nereus - Yahoo Finance
Vanda Pharmaceuticals stock (US92178N1054): Regulatory setback, sharp drop and rising short interest - AD HOC NEWS
Vanda: A Long-Term Pharma Growth Idea, Despite Q1 Earnings Miss (NASDAQ:VNDA) - Seeking Alpha
Vanda targets $240M-$290M 2026 revenue as it introduces $10M-$30M NEREUS sales outlook - MSN
HC Wainwright Brokers Lower Earnings Estimates for VNDA - MarketBeat
State Street (VNDA) discloses 3.02M shares, 5.1% ownership on 13G - Stock Titan
Earnings call transcript: Vanda Pharmaceuticals Q1 2026 misses EPS forecast, stock drops By Investing.com - Investing.com South Africa
Vanda Pharmaceuticals Inc (VNDA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Vanda Pharmaceuticals Inc 주식 (VNDA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Moran Kevin Patrick | SVP, CFO & Treasurer |
Mar 02 '26 |
Sale |
8.27 |
42,442 |
350,821 |
411,380 |
| Wijkstrom Joakim | SVP, Chief Marketing Officer |
Mar 02 '26 |
Sale |
8.27 |
30,800 |
254,590 |
333,469 |
| Polymeropoulos Mihael Hristos | President and CEO |
Mar 02 '26 |
Sale |
8.17 |
156,235 |
1,276,971 |
2,704,496 |
| Birznieks Gunther | SVP, Business Development |
Mar 02 '26 |
Sale |
8.27 |
42,431 |
350,730 |
494,197 |
1.27%
1.43%
자본화:
|
볼륨(24시간):